By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:



Company News
Retrophin (RTRX) Snags Cholic Acid Rights From Asklepion Pharmaceuticals in $78 Million Deal 1/12/2015 6:28:09 AM
Ligand Pharmaceuticals Inc. (LGND) Partner Retrophin (RTRX) Receives Orphan Drug Designation For Sparsentan 1/9/2015 11:17:23 AM
Retrophin (RTRX) Provides Corporate Update 1/9/2015 9:25:45 AM
More Trouble for Retrophin (RTRX) Founder 1/8/2015 7:06:18 AM
Retrophin (RTRX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 1/7/2015 11:57:59 AM
Retrophin (RTRX) Announces Addition To The NASDAQ Biotechnology Index 12/16/2014 11:11:57 AM
Ex-Retrophin (RTRX) CEO Sold Stock While Urging Investors To Buy 11/26/2014 6:21:33 AM
Retrophin (RTRX) Names Margaret Valeur-Jensen, Ph.D. As General Counsel 11/19/2014 12:07:49 PM
Retrophin (RTRX) Names Laura M. Clague As Chief Financial Officer 11/17/2014 11:24:22 AM
Retrophin (RTRX) Reports Third Quarter 2014 Financial Results 11/14/2014 10:59:19 AM